CA2226870A1 - Epidural administration of therapeutic compounds with sustained rate of release - Google Patents

Epidural administration of therapeutic compounds with sustained rate of release

Info

Publication number
CA2226870A1
CA2226870A1 CA002226870A CA2226870A CA2226870A1 CA 2226870 A1 CA2226870 A1 CA 2226870A1 CA 002226870 A CA002226870 A CA 002226870A CA 2226870 A CA2226870 A CA 2226870A CA 2226870 A1 CA2226870 A1 CA 2226870A1
Authority
CA
Canada
Prior art keywords
release
therapeutic compounds
sustained rate
epidural administration
opioid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002226870A
Other languages
French (fr)
Other versions
CA2226870C (en
Inventor
Sinil Kim
Andras Gruber
Sharad B. Murdande
Taehee Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Depotech Corporation
Sinil Kim
Andras Gruber
Sharad B. Murdande
Taehee Kim
Skyepharma Inc.
Pacira Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Depotech Corporation, Sinil Kim, Andras Gruber, Sharad B. Murdande, Taehee Kim, Skyepharma Inc., Pacira Pharmaceuticals, Inc. filed Critical Depotech Corporation
Publication of CA2226870A1 publication Critical patent/CA2226870A1/en
Application granted granted Critical
Publication of CA2226870C publication Critical patent/CA2226870C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Abstract

A drug delivery system provides sustained-release delivery of therapeutic biologically active compounds administered epidurally. In the preferred embodiment the biologically active coupound is an opioid, which is encapsulated within the non-concentric internal aqueous chambers or bilayers of multivesicular liposomes. The opioid is released over an extended period of time when the liposomes are introduced epidurally as a single dose for sustained analgesia.
CA002226870A 1995-07-14 1996-07-12 Epidural administration of therapeutic compounds with sustained rate of release Expired - Lifetime CA2226870C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/502,569 US5931809A (en) 1995-07-14 1995-07-14 Epidural administration of therapeutic compounds with sustained rate of release
US08/502,569 1995-07-14
PCT/US1996/011642 WO1997003652A1 (en) 1995-07-14 1996-07-12 Epidural administration of therapeutic compounds with sustained rate of release

Publications (2)

Publication Number Publication Date
CA2226870A1 true CA2226870A1 (en) 1997-02-06
CA2226870C CA2226870C (en) 2005-05-17

Family

ID=23998405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002226870A Expired - Lifetime CA2226870C (en) 1995-07-14 1996-07-12 Epidural administration of therapeutic compounds with sustained rate of release

Country Status (13)

Country Link
US (2) US5931809A (en)
EP (2) EP2036542B1 (en)
JP (4) JP4592119B2 (en)
KR (2) KR20060012027A (en)
CN (1) CN1085944C (en)
AU (1) AU699177B2 (en)
BR (1) BR9609717A (en)
CA (1) CA2226870C (en)
HK (1) HK1014881A1 (en)
NO (1) NO326261B1 (en)
NZ (1) NZ312963A (en)
RU (1) RU2215522C2 (en)
WO (1) WO1997003652A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6440455B1 (en) 1997-09-02 2002-08-27 Children's Medical Center Corporation Methods for modulating the axonal outgrowth of central nervous system neurons
US6306432B1 (en) * 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
EP2198854B1 (en) * 1997-09-18 2011-11-30 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
JP4575592B2 (en) 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド Production of multivesicular liposomes
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
KR100417489B1 (en) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 Opioid agonist/antagonist combinations
DE69935435T2 (en) * 1998-08-12 2007-12-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ammonium sulfate gradient prepared liposomal analgesic compositions
CA2376849C (en) * 1999-06-24 2008-10-14 Kyowa Hakko Kogyo Co., Ltd. Method of inhibiting leakage of drug encapsulated in liposomes
HU230828B1 (en) * 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
CN1434706A (en) 1999-12-23 2003-08-06 神经化学公司 Compounds and methods for modulating cerebral anyloid angiopathy
US7172871B1 (en) 2000-09-07 2007-02-06 Children's Medical Center Corporation Methods and compositions for modulating axonal outgrowth of central nervous system neurons
ES2689704T3 (en) * 2000-11-30 2018-11-15 Vectura Limited Particles for use in a pharmaceutical composition
ES2474199T3 (en) 2000-11-30 2014-07-08 Vectura Limited Pharmaceutical compositions for inhalation
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
CA2708900C (en) 2002-04-05 2019-06-04 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US8708993B1 (en) * 2003-10-15 2014-04-29 Physician Technologies, Inc. Infusion catheter procedure and system
US8912144B2 (en) 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
ATE401054T1 (en) * 2004-06-04 2008-08-15 Camurus Ab LIQUID DEPOSIT FORMULATIONS
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
US20070253994A1 (en) * 2006-04-28 2007-11-01 Medtronic, Inc. Intraspinal Drug Delivery Methods and Devices To Alleviate Chronic Pelvic Pain
CA2661302A1 (en) * 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8940315B2 (en) * 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
PT2405915T (en) 2009-03-10 2019-01-29 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB2490084A (en) * 2010-02-22 2012-10-17 Edge Therapeutics Inc Methods and compositions to treat hemorrhagic conditions of the brain
CN102462662A (en) * 2010-08-16 2012-05-23 重庆富进生物医药有限公司 Liposome-encapsulated recombinant human ciliary neurotrophic factor
BR112013016365A2 (en) * 2010-12-27 2018-06-26 Terumo Corp liposome composition and process for production thereof
WO2012118796A1 (en) 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Compositions for controlling neuronal outgrowth
EP2846772A4 (en) 2012-05-10 2015-12-30 Painreform Ltd Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
DK2864360T3 (en) 2012-06-25 2017-12-18 Brigham & Womens Hospital Inc TARGETED THERAPY
US9937164B2 (en) 2012-07-26 2018-04-10 Camurus Ab Opioid formulations
JP6698015B2 (en) 2013-03-12 2020-05-27 ザ ジェネラル ホスピタル コーポレイション Modified mullerian inhibitory substance (MIS) protein and use thereof for the treatment of diseases
EP3143988A1 (en) 2013-03-14 2017-03-22 Fresenius Kabi Deutschland GmbH Injectable morphine formulations
AU2014230836C1 (en) 2013-03-14 2018-12-20 Fresenius Kabi Deutschland Gmbh Packaging system for oxygen-sensitive drugs
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
ES2912283T3 (en) 2013-12-11 2022-05-25 Massachusetts Gen Hospital Use of müllerian inhibitory substance (MIS)-type proteins for contraception and preservation of ovarian reserve
CN111432807A (en) 2017-10-06 2020-07-17 铸造疗法股份有限公司 Implantable reservoir for controlled release of therapeutic agents
KR102168204B1 (en) 2018-11-30 2020-10-20 동국제약 주식회사 Preparation method of sustatined release liposomal formulations
US20220273568A1 (en) * 2019-07-12 2022-09-01 Pacira Pharmaceuticals, Inc. Multivesicular liposome formulations of dexmedetomidine
WO2021028916A1 (en) * 2019-08-12 2021-02-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Pharmaceutical compositions comprising a combination of opioid antagonists
US20230052318A1 (en) * 2020-01-06 2023-02-16 Pacira Pharmaceuticals, Inc. Treatment of pain associated with cesarean section surgery with sustained-release liposomal anesthetic compositions
EP4087554A4 (en) 2020-01-10 2024-01-17 Pacira Pharmaceuticals Inc Treatment of pain by subarachnoid administration of sustained-release liposomal anesthetic compositions
US20230130180A1 (en) 2020-01-10 2023-04-27 Pacira Pharmaceuticals, Inc. Treatment of pain by administration of sustained-release liposomal anesthetic compositions
WO2022150708A1 (en) 2021-01-11 2022-07-14 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
KR20220125027A (en) 2021-03-04 2022-09-14 포항공과대학교 산학협력단 A manufacturing method for liposom drug delivery structure based on liposomal bupivacaine and slow release preparation
CN117320696A (en) 2021-03-19 2023-12-29 帕西拉制药股份有限公司 Treatment of pain in pediatric patients by administration of a slow release liposomal anesthetic composition
CN114949220B (en) * 2022-01-30 2023-09-22 浙江大学 PH response analgesic for targeting damaged segment dorsal root ganglion and application thereof
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35192A (en) * 1862-05-06 Improved nutmeg-grater
CH588887A5 (en) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (en) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4452025A (en) 1979-07-18 1984-06-05 Lew Hyok S Self-interlocking grille
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4578384A (en) 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4696258A (en) 1984-04-04 1987-09-29 The Magrath Company Method and substance for the detection of cows in estrus
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
FR2585246A1 (en) 1985-07-26 1987-01-30 Cortial PROCESS FOR OBTAINING SOLID PHARMACEUTICAL FORMS WITH PROLONGED RELEASE
JPH0645396B2 (en) 1985-09-04 1994-06-15 ザ・コカ−コ−ラ・カンパニ− Connection device
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
FR2592791A1 (en) * 1986-01-14 1987-07-17 Ire Celltarg Sa PHARMACEUTICAL COMPOSITION CONTAINING A LOCAL ANESTHETIC AND / OR A CENTRAL ANALGESIC ENCAPSULATED IN LIPOSOMES
US5244678A (en) * 1986-01-14 1993-09-14 Ire-Celltarg S.A. Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic encapsulated in liposomes
IL78826A (en) * 1986-05-19 1991-05-12 Yissum Res Dev Co Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
JP2666345B2 (en) * 1987-04-16 1997-10-22 武田薬品工業株式会社 Liposome preparation and method for producing the same
US5261903A (en) * 1988-04-11 1993-11-16 M.D. Inc. Composite anesthetic article and method of use
EP0376999A1 (en) * 1988-04-27 1990-07-11 Baker Cummins Pharmaceuticals, Inc. Method of reversing the side effects of epidural analgesics
BE1001869A3 (en) * 1988-10-12 1990-04-03 Franz Legros METHOD OF PACKAGING liposomal AMINOGLUCOSIDIQUES ANTIBIOTICS IN PARTICULAR THE GENTAMYCIN.
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US4921853A (en) * 1988-11-14 1990-05-01 Michigan State University Method for producing analgesia in mammals
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
SE8904298D0 (en) 1989-12-21 1989-12-21 Astra Ab NEW COMPOUNDS
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
USRE35192E (en) 1990-11-13 1996-03-26 Phoenix Surgical Products, Inc. Post-surgical anesthesia at a continuous and progressively decreasing administration rate
CH683149A5 (en) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Process for the preparation of microspheres of a biodegradable polymeric material.
CA2151741C (en) * 1991-12-30 2001-12-11 Alan Justice Methods of producing analgesia and enhancing opiate analgesia
AU668384B2 (en) * 1992-03-12 1996-05-02 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
WO1993020802A1 (en) * 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
US5922340A (en) * 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
WO1994023697A1 (en) * 1993-04-22 1994-10-27 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
BR9408072A (en) 1993-11-16 1997-08-12 Depotech Corp Vesicles with controlled release of assets
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
DK1336409T3 (en) * 1995-06-27 2007-08-13 Eisai R&D Man Co Ltd Compositions of formulations for the preparation of analgesics and for the prevention of progressive neuropathic pain disorders
WO1997002447A1 (en) * 1995-07-03 1997-01-23 Eidsmore Paul G Spring loaded bellows regulator
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
JP4478127B2 (en) * 2006-07-04 2010-06-09 サカエ理研工業株式会社 Vehicle door handle device
KR101989059B1 (en) 2012-08-22 2019-06-14 삼성디스플레이 주식회사 Cascade-type compound and organic light emitting diode comprising the same

Also Published As

Publication number Publication date
US5931809A (en) 1999-08-03
NO980146D0 (en) 1998-01-13
NZ312963A (en) 1999-06-29
EP0839027A1 (en) 1998-05-06
US6428529B1 (en) 2002-08-06
RU2215522C2 (en) 2003-11-10
NO980146L (en) 1998-03-13
CN1085944C (en) 2002-06-05
NO326261B1 (en) 2008-10-27
KR100593722B1 (en) 2007-04-25
EP0839027A4 (en) 2000-12-06
US20020065506A1 (en) 2002-05-30
BR9609717A (en) 1999-12-21
AU6491196A (en) 1997-02-18
JP2010031030A (en) 2010-02-12
AU699177B2 (en) 1998-11-26
KR20060012027A (en) 2006-02-06
WO1997003652A1 (en) 1997-02-06
JP4592119B2 (en) 2010-12-01
JP2010043104A (en) 2010-02-25
JP2008143911A (en) 2008-06-26
EP2036542B1 (en) 2016-04-20
EP2036542A1 (en) 2009-03-18
CA2226870C (en) 2005-05-17
JPH11508900A (en) 1999-08-03
MX9800391A (en) 1998-09-30
KR19990028906A (en) 1999-04-15
CN1195286A (en) 1998-10-07
HK1014881A1 (en) 1999-10-08

Similar Documents

Publication Publication Date Title
CA2226870A1 (en) Epidural administration of therapeutic compounds with sustained rate of release
IL119627A0 (en) Controlled-release pharmaceutical preparations
NZ508526A (en) Opioid formulations for treating pain
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
CA2304096A1 (en) Sustained-release liposomal anesthetic compositions
CA2240329A1 (en) Improved delivery of multiple doses of medications
AU6136199A (en) Dosage form comprising therapeutic formulation
MY125662A (en) Pharmaceutical formulations containing darifenacin
CA2307018A1 (en) Osmotic medicament releasing system
GR3033325T3 (en) Controlled release preparation containing a salt of morphine.
CA2253980A1 (en) Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof
ATE143599T1 (en) CODEINEONE DERIVATIVES AND THEIR PHARMACEUTICAL USE
CA2264852A1 (en) Use of methylphenidate or a pharmaceutically acceptable salt thereof
AU2223095A (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
CZ289395A3 (en) Transdermic therapeutic system for administration of serotonin agonists
EP1782798A3 (en) Ascending-dose dosage form
IL125104A0 (en) Agent for prophylaxis and treatment of diabetic complications
EP0300806B1 (en) Opioid analgesic liposomal delivery-release system
WO1997018840A3 (en) Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
ZA96260B (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazole or one of its pharmaceutically acceptable salts
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
RU97109804A (en) METHOD OF ANESTHESIA
WO1993015752A1 (en) Anti-neuropathic composition
RU98109932A (en) APPLICATION OF 1- (2-NAFT-2-YLETHYL) -4- (3-TRIFLUOROMETHYLPHENYL) -1,2,3,6-TETHRHYDROPYRIDINE FOR THE PRODUCTION OF MEDICINES FOR THE TREATMENT OF LATERAL AMYOTRAFRAZIC
AU4391196A (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160712